Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GSK
STRONG BUYGSK plc · Healthcare · United Kingdom · $105.2B · Avg Vol: $202M/d
COMPANY DESCRIPTION
GSK plc is a global biopharmaceutical giant focused on the research, development, and commercialization of innovative vaccines and specialty medicines. The company holds a dominant market position in the global vaccine industry and is a leader in HIV therapeutics through its majority-owned ViiV Healthcare joint venture. Following the spin-off of its consumer healthcare division, GSK operates as a pure-play, research-driven healthcare leader with robust R&D pipelines in infectious diseases and immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.7B | 40.0B | 41.4B | 43.1B | 3.7% | 43.3B | 44.7B | 47.0B | 4.4% |
| EPS | 20.04 | 6.50 | 3.40 | 7.46 | -28.1% | 3.75 | 7.14 | 7.65 | 1.3% |
| Shares | 2.0B | 2.0B | 2.0B | 2.0B | 0.0% | 2.0B | — | — | — |
| Debt | 27.7B | 23.8B | 22.4B | 23.4B | -5.5% | 25.2B | — | — | — |
| Equity | 14.0B | 17.6B | 18.0B | 21.6B | 15.6% | — | — | — | — |
| Op CF | 9.8B | 8.9B | 8.6B | 10.2B | 1.5% | 10.2B | — | — | — |
| Inv CF | -11.6B | -2.1B | -1.6B | -5.6B | — | — | — | — | — |
| Fin CF | 1.1B | -7.4B | -6.2B | -4.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GSK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GSK | GSK plc(you) | $105.2B | 95 | STRONG BUY |
| SNY | Sanofi | $102.8B | 96 | STRONG BUY |
| PFE.MX | Pfizer Inc. | $137.8B | 95 | STRONG BUY |
| BMY | Bristol-Myers Squibb Company | $117.5B | 99 | STRONG BUY |
| GILD | Gilead Sciences, Inc. | $158.8B | 95 | STRONG BUY |
| AMGN.MX | Amgen Inc. | $192.8B | 96 | STRONG BUY |
| BAYN.DE | Bayer Aktiengesellschaft | $52.6B | 91 | STRONG BUY |
| NVON.MX | Novo Nordisk A/S | $212.5B | 90 | STRONG BUY |
| ROP.SW | Roche Holding AG | $323.7B | 97 | STRONG BUY |
| MRK.MX | Merck & Co., Inc. | $316.3B | 98 | STRONG BUY |
Peer medians: ROE 2.7% · P/E 22.9x · Gross margin 47.5%